These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25433778)

  • 1. [Positron emission tomography combined with computed tomography in the initial evaluation and response assessment in primary central nervous system lymphoma].
    Mercadal S; Cortés-Romera M; Vélez P; Climent F; Gámez C; González-Barca E
    Med Clin (Barc); 2015 Jun; 144(11):503-6. PubMed ID: 25433778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (11)C-methionine PET/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate.
    Jang SJ; Lee KH; Lee JY; Choi JY; Kim BT; Kim SJ; Kim WS
    Clin Nucl Med; 2012 Oct; 37(10):e241-4. PubMed ID: 22955084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of
    de-Bonilla-Damiá Á; Fernández-López R; Capote-Huelva FJ; de la Cruz-Vicente F; Egea-Guerrero JJ; Borrego-Dorado I
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):298-303. PubMed ID: 28438519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
    Akkas BE; Vural GU
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAC y PET/TC con 18-FDG para evaluar la respuesta al tratamiento en linfoma de Hodgkin y no Hodgkin.
    Vargas-Partida T; Hernández-Cruz M; Ruiz-Eng R; Montiel-Jarquín ÁJ; Vázquez-Cruz E; López-Colombo A
    Gac Med Mex; 2019; 155(4):386-390. PubMed ID: 31486785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.
    Deguchi S; Nakashima K; Muramatsu K; Mitsuya K; Oishi T; Shirata K; Hayashi N; Sugino T; Endo M; Nakasu Y
    J Clin Neurosci; 2019 Nov; 69():43-50. PubMed ID: 31427235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.
    Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.
    Wu X; Kellokumpu-Lehtinen PL; Pertovaara H; Korkola P; Soimakallio S; Eskola H; Dastidar P
    NMR Biomed; 2011 Dec; 24(10):1181-90. PubMed ID: 21387451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary central nervous system lymphoma with lymphomatosis cerebri in an immunocompetent child: MRI and 18F-FDG PET-CT findings.
    Jain TK; Sharma P; Suman SK; Faizi NA; Bal C; Kumar R
    Rev Esp Med Nucl Imagen Mol; 2013; 32(6):394-6. PubMed ID: 23743243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim
    Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
    Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
    [No Abstract]   [Full Text] [Related]  

  • 17. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
    Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
    Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
    González-Barca E; Canales M; Cortés M; Vidal MJ; Salar A; Oriol A; Bargay J; Bello JL; Sánchez JJ; Tomás JF; Donato E; Ferrer S; Caballero D;
    Nucl Med Commun; 2013 Oct; 34(10):946-52. PubMed ID: 23880897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
    Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
    Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.